Advances in pharmacologic stress agents: focus on regadenoson

Area of Science:

• Nuclear Medicine
• Cardiology
• Pharmacology

Background:

• Myocardial perfusion imaging is crucial for diagnosing and managing coronary artery disease.
• Traditional pharmacologic stress agents like adenosine and dipyridamole have limitations, including frequent side effects and complex protocols.
• There is a need for safer, more effective, and patient-friendly stress agents.

Purpose of the Study:

• To review the limitations of current pharmacologic stress agents used in myocardial perfusion imaging.
• To assess the potential of A(2A) receptor agonists, specifically regadenoson, as improved stress agents.
• To evaluate the practical aspects and impact of regadenoson use in nuclear medicine departments.

Main Methods:

• Review of existing literature on pharmacologic stress agents for myocardial perfusion imaging.
• Assessment of adenosine receptor pharmacology and the role of A(2A) receptor selectivity.
• Evaluation of clinical trial data for regadenoson, comparing its efficacy and safety to adenosine.

Main Results:

• Regadenoson, a selective A(2A) agonist, demonstrates non-inferiority to adenosine in detecting reversible myocardial perfusion defects.
• Patients reported greater comfort during regadenoson stress compared to adenosine infusion.
• Regadenoson's fixed-dose, rapid injection protocol simplifies procedures and is independent of patient weight or renal function.

Conclusions:

• A(2A) receptor agonists like regadenoson represent a significant improvement over older, non-selective agents.
• Regadenoson offers a safer, more tolerable, and procedurally simpler option for pharmacologic stress in myocardial perfusion imaging.
• The use of regadenoson has the potential to streamline nuclear medicine workflows and reduce procedural costs.